ARTICLE | Finance
A new hat trick
VC Hatteras earmarks 20% of new fund for high-risk early biopharma projects
August 22, 2011 7:00 AM UTC
Early stage VC Hatteras Venture Partners announced a first close of its fourth fund, raising $74 million of a planned of $125 million that will be invested in fledgling companies. The firm said 20% of the fund will be earmarked for making small make-or-break bets on particularly embryonic projects.
Over the last 11 years, Hatteras has made its living investing in early stage life science assets and plans to do more of the same with Hatteras Venture Partners IV, according to the firm's Clay Thorpe...